- C. E. Rudd, A. Taylor, H. Schneider, CD28 and CTLA-4
coreceptor expression and signal transduction.Immunol. Rev.
229 ,12–26 (2009). doi:10.1111/j.1600-065X.2009.00770.x;
pmid: 19426212 - G. J. Freemanet al., Cloning of B7-2: A CTLA-4 counter-
receptor that costimulates human T cell proliferation.Science
262 , 909–911 (1993). doi:10.1126/science.7694363;
pmid: 7694363 - P. S. Linsleyet al., CTLA-4 is a second receptor for the B cell
activation antigen B7.J. Exp. Med. 174 , 561–569 (1991).
doi:10.1084/jem.174.3.561; pmid: 1714933 - P. S. Linsleyet al., Human B7-1 (CD80) and B7-2 (CD86) bind
with similar avidities but distinct kinetics to CD28 and CTLA-4
receptors.Immunity 1 , 793–801 (1994). doi:10.1016/S1074-
7613(94)80021-9; pmid: 7534620 - E. A. Tivolet al., Loss of CTLA-4 leads to massive
lymphoproliferation and fatal multiorgan tissue destruction,
revealing a critical negative regulatory role of CTLA-4.
Immunity 3 , 541–547 (1995). doi:10.1016/1074-7613(95)
90125-6; pmid: 7584144 - P. Waterhouseet al., Lymphoproliferative disorders with early
lethality in mice deficient in Ctla-4.Science 270 , 985– 988
(1995). doi:10.1126/science.270.5238.985; pmid: 7481803 - G. Q. Phanet al., Cancer regression and autoimmunity induced
by cytotoxic T lymphocyte-associated antigen 4 blockade in
patients with metastatic melanoma.Proc. Natl. Acad. Sci. U.S.A.
100 ,8372–8377 (2003). doi:10.1073/pnas.1533209100;
pmid: 12826605 - H. Nishimuraet al., Autoimmune dilated cardiomyopathy in
PD-1 receptor-deficient mice.Science 291 , 319–322 (2001).
doi:10.1126/science.291.5502.319;pmid: 11209085 - H. Nishimura, M. Nose, H. Hiai, N. Minato, T. Honjo,
Development of lupus-like autoimmune diseases by disruption
of the PD-1 gene encoding an ITIM motif-carrying
immunoreceptor.Immunity 11 ,141–151 (1999). doi:10.1016/
S1074-7613(00)80089-8; pmid: 10485649 - H. Donget al., B7-H1 determines accumulation and deletion of
intrahepatic CD8(+) T lymphocytes.Immunity 20 , 327– 336
(2004). doi:10.1016/S1074-7613(04)00050-0;
pmid: 15030776 - J. M. Taubeet al., Colocalization of inflammatory response with
B7-h1 expression in human melanocytic lesions supports an
adaptive resistance mechanism of immune escape.Sci. Transl.
Med. 4 , 127ra37 (2012). doi:10.1126/scitranslmed.3003689;
pmid: 22461641 - P. C. Tumehet al., PD-1 blockade induces responses by
inhibiting adaptive immune resistance.Nature 515 , 568– 571
(2014). doi:10.1038/nature13954; pmid: 25428505 - M. L. Brozet al., Dissecting the tumor myeloid compartment
reveals rare activating antigen-presenting cells critical for
T cell immunity.Cancer Cell 26 , 638–652 (2014). doi:10.1016/
j.ccell.2014.09.007; pmid: 25446897 - C. S. Garriset al., Successful anti-PD-1 cancer immunotherapy
requires T cell-dendritic cell crosstalk involving the cytokines
IFN-gamma and IL-12.Immunity 49 ,1148–1161.e7 (2018).
doi:10.1016/j.immuni.2018.09.024; pmid: 30552023 - K. C. Barryet al., A natural killer-dendritic cell axis defines
checkpoint therapy-responsive tumor microenvironments.
Nat. Med. 24 , 1178–1191 (2018). doi:10.1038/s41591-018-
0085-8; pmid: 29942093 - I. Siddiquiet al., Intratumoral Tcf1+PD-1+CD8+T cells with
stem-like properties promote tumor control in response to
vaccination and checkpoint blockade immunotherapy.
Immunity 50 , 195–211.e10 (2019). doi:10.1016/
j.immuni.2018.12.021; pmid: 30635237 - M. V. Goldberget al., Role of PD-1 and its ligand, B7-H1, in
early fate decisions of CD8 T cells.Blood 110 , 186–192 (2007).
doi:10.1182/blood-2006-12-062422; pmid: 17392506 - F. Tsushimaet al., Interaction between B7-H1 and
PD-1 determines initiation and reversal of T-cell anergy.
Blood 110 , 180–185 (2007). doi:10.1182/blood-2006-11-
060087 ; pmid: 17289811 - B. T. Fifeet al., Interactions between PD-1 and PD-L1 promote
tolerance by blocking the TCR-induced stop signal.
Nat. Immunol. 10 , 1185–1192 (2009). doi:10.1038/ni.1790;
pmid: 19783989 - K. Staveley-O’Carrollet al., Induction of antigen-specific T cell
anergy: An early event in the course of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 95 , 1178–1183 (1998).
doi:10.1073/pnas.95.3.1178; pmid: 9448305 - E. W. Robertset al., Critical role for CD103(+)/CD141(+)
dendritic cells bearing CCR7 for tumor antigen trafficking and
priming of T cell immunity in melanoma.Cancer Cell 30 ,
324 – 336 (2016). doi:10.1016/j.ccell.2016.06.003;
pmid: 27424807- H. Salmonet al., Expansion and activation of CD103(+)
dendritic cell progenitors at the tumor site enhances tumor
responses to therapeutic PD-L1 and BRAF inhibition.Immunity
44 , 924–938 (2016). doi:10.1016/j.immuni.2016.03.012;
pmid: 27096321 - J. Liuet al., Batf3+DCs and type I IFN are critical for the
efficacy of neoadjuvant cancer immunotherapy.
OncoImmunology 8 , e1546068 (2018). doi:10.1080/
2162402X.2018.1546068; pmid: 30713806 - M. F. Fransenet al., Tumor-draining lymph nodes are pivotal in
PD-1/PD-L1 checkpoint therapy.JCI Insight 3 , e124507 (2018).
doi:10.1172/jci.insight.124507; pmid: 30518694 - S. Thangadaet al., Cell-surface residence of sphingosine
1-phosphate receptor 1 on lymphocytes determines
lymphocyte egress kinetics.J. Exp. Med. 207 , 1475– 1483
(2010). doi:10.1084/jem.20091343; pmid: 20584883 - K. E. Yostet al., Clonal replacement of tumor-specific T cells
following PD-1 blockade.Nat. Med. 25 , 1251–1259 (2019).
doi:10.1038/s41591-019-0522-3; pmid: 31359002 - P. M. Fordeet al., Neoadjuvant PD-1 blockade in resectable
lung cancer.N. Engl. J. Med. 378 , 1976–1986 (2018).
doi:10.1056/NEJMoa1716078; pmid: 29658848 - A. O. Kamphorstet al., Rescue of exhausted CD8 T cells by
PD-1-targeted therapies is CD28-dependent.Science 355 ,
1423 – 1427 (2017). doi:10.1126/science.aaf0683;
pmid: 28280249 - A. Memarnejadianet al., PD-1 blockade promotes epitope
spreading in anticancer CD8+T cell responses by preventing
fratricidal death of subdominant clones to relieve
immunodomination.J. Immunol. 199 , 3348–3359 (2017).
doi:10.4049/jimmunol.1700643; pmid: 28939757 - J. Zhanget al., Compartmental analysis of T cell clonal
dynamics as a function of pathologic response to neoadjuvant
PD-1 blockade in resectable non-small cell lung cancer.
Clin. Cancer Res.clincanres.2931.2019; Epub ahead of print
(2019). doi:10.1158/1078-0432.CCR-19-2931; pmid: 31754049 - R. N. Amariaet al., Neoadjuvant immune checkpoint blockade
in high-risk resectable melanoma.Nat. Med. 24 , 1649– 1654
(2018). doi:10.1038/s41591-018-0197-1; pmid: 30297909 - C. U. Blanket al., Neoadjuvant versus adjuvant ipilimumab plus
nivolumab in macroscopic stage III melanoma.Nat. Med. 24 ,
1655 – 1661 (2018). doi:10.1038/s41591-018-0198-0;
pmid: 30297911 - A. C. Huanget al., A single dose of neoadjuvant PD-1 blockade
predicts clinical outcomes in resectable melanoma.Nat. Med.
25 , 454–461 (2019). doi:10.1038/s41591-019-0357-y;
pmid: 30804515 - E. A. Rozemanet al., Identification of the optimal combination
dosing schedule of neoadjuvant ipilimumab plus nivolumab in
macroscopic stage III melanoma (OpACIN-neo): A multicentre,
phase 2, randomised, controlled trial.Lancet Oncol. 20 ,
948 – 960 (2019). doi:10.1016/S1470-2045(19)30151-2;
pmid: 31160251 - J. Larkinet al., Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma.N. Engl. J. Med. 373 ,
23 – 34 (2015). doi:10.1056/NEJMoa1504030; pmid: 26027431 - A. Necchiet al., Pembrolizumab as neoadjuvant therapy before
radical cystectomy in patients with muscle-invasive urothelial
bladder carcinoma (PURE-01): An open-label, single-arm,
phase II study.J. Clin. Oncol. 36 , 3353–3360 (2018).
doi: 10 .1200/JCO.18.01148; pmid:^30343614 - T. F. Cloughesyet al., Neoadjuvant anti-PD-1 immunotherapy
promotes a survival benefit with intratumoral and systemic
immune responses in recurrent glioblastoma.Nat. Med. 25 ,
477 – 486 (2019). doi:10.1038/s41591-018-0337-7;
pmid: 30742122 - K. A. Schalperet al., Neoadjuvant nivolumab modifies the
tumor immune microenvironment in resectable glioblastoma.
Nat. Med. 25 ,470–476 (2019). doi:10.1038/s41591-018-0339-5;
pmid: 30742120 - R. N. Amariaet al., Neoadjuvant systemic therapy in
melanoma: Recommendations of the International Neoadjuvant
Melanoma Consortium.Lancet Oncol. 20 , e378–e389 (2019).
doi:10.1016/S1470-2045(19)30332-8; pmid: 31267972 - F. Petrelliet al., Correlation of pathologic complete response
with survival after neoadjuvant chemotherapy in bladder
cancer treated with cystectomy: A meta-analysis.Eur. Urol. 65 ,
350 – 357 (2014). doi:10.1016/j.eururo.2013.06.049;
pmid: 23849998 - Z. Liet al., Correlation of pathological complete response with
survival after neoadjuvant chemotherapy in gastric or
gastroesophageal junction cancer treated with radical surgery:
A meta-analysis.PLOS ONE 13 , e0189294 (2018). doi:10.1371/
journal.pone.0189294; pmid: 29370182- L. Springet al., Pathologic complete response after
neoadjuvant chemotherapy and long-term outcomes among
young women with breast cancer.J. Natl. Compr. Canc. Netw.
15 , 1216–1223 (2017). doi:10.6004/jnccn.2017.0158;
pmid: 28982747 - G. Mouilletet al., Pathologic complete response to
preoperative chemotherapy predicts cure in early-stage
non-small-cell lung cancer: Combined analysis of two IFCT
randomized trials.J. Thorac. Oncol. 7 , 841–849 (2012).
doi:10.1097/JTO.0b013e31824c7d92; pmid: 22722786
62.M. D. Hellmannet al., Pathological response after neoadjuvant
chemotherapy in resectable non-small-cell lung cancers:
Proposal for the use of major pathological response as a
surrogate endpoint.Lancet Oncol. 15 , e42–e50 (2014).
doi:10.1016/S1470-2045(13)70334-6; pmid: 24384493 - W. F. Symmanset al., Measurement of residual breast cancer
burden to predict survival after neoadjuvant chemotherapy.
J. Clin. Oncol. 25 , 4414–4422 (2007). doi:10.1200/
JCO.2007.10.6823; pmid: 17785706 - M. T. Tetzlaffet al., Pathological assessment of resection
specimens after neoadjuvant therapy for metastatic
melanoma.Ann. Oncol. 29 , 1861–1868 (2018). doi:10.1093/
annonc/mdy226; pmid: 29945191 - Y. Quet al., Pathologic assessment after neoadjuvant
chemotherapy for NSCLC: Importance and implications of
distinguishing adenocarcinoma from squamous cell carcinoma.
J. Thorac. Oncol. 14 , 482–493 (2019). doi:10.1016/
j.jtho.2018.11.017; pmid: 30503889 - T. R. Cottrellet al., Pathologic features of response to
neoadjuvant anti-PD-1 in resected non-small-cell lung
carcinoma: A proposal for quantitative immune-related
pathologic response criteria (irPRC).Ann. Oncol. 29 ,
1853 – 1860 (2018). doi:10.1093/annonc/mdy218;
pmid: 29982279 - J. E. Steinet al., Pan-tumor pathologic scoring of response to
PD-(L)1 blockade.Clin. Cancer Res.10.1158/1078-0432.CCR-
19-2379 (2019). doi:10.1158/1078-0432.CCR-19-2379;
pmid: 31672770 - S. L. Topalianet al., Nivolumab (Nivo) as neoadjuvant therapy
in patients with resectable Merkel cell carcinoma (MCC) in
CheckMate 358.J. Clin. Oncol. 36 , 9505–9505 (2018).
doi:10.1200/JCO.2018.36.15_suppl.9505 - C. Sautès-Fridman, F. Petitprez, J. Calderaro, W. H. Fridman,
Tertiary lymphoid structures in the era of cancer
immunotherapy.Nat. Rev. Cancer 19 , 307–325 (2019).
doi: 10 .1038/s41568-019-0144-6; pmid: 31092904 - T. Okazaki, A. Maeda, H. Nishimura, T. Kurosaki, T. Honjo,
PD-1 immunoreceptor inhibits B cell receptor-mediated
signaling by recruiting src homology 2-domain-containing
tyrosine phosphatase 2 to phosphotyrosine.Proc. Natl. Acad.
Sci. U.S.A. 98 , 13866–13871 (2001). doi:10.1073/
pnas.231486598; pmid: 11698646 - W. Damskyet al., B cell depletion or absence does not impede
anti-tumor activity of PD-1 inhibitors.J. Immunother. Cancer 7 ,
153 (2019). doi:10.1186/s40425-019-0613-1; pmid: 31200747 - J. Grisset al., B cells sustain inflammation and predict
response to immune checkpoint blockade in human melanoma.
Nat. Commun. 10 , 4186 (2019). doi:10.1038/s41467-019-
12160-2; pmid: 31519915 - J. E. Steinet al., Major pathologic response on biopsy (MPRbx)
in patients with advanced melanoma treated with anti-PD-1:
Evidence for an early, on-therapy biomarker of response.
Ann. Oncol. 30 , 589–596 (2019). doi:10.1093/annonc/
mdz019; pmid: 30689736 - E. Z. Keung, E. U. Ukponmwan, A. P. Cogdill, J. A. Wargo, The
rationale and emerging use of neoadjuvant immune checkpoint
blockade for solid malignancies.Ann. Surg. Oncol. 25 ,
1814 – 1827 (2018). doi:10.1245/s10434-018-6379-8;
pmid: 29500764 - J. S. O’Donnell, E. P. Hoefsmit, M. J. Smyth, C. U. Blank,
M. W. L. Teng, The promise of neoadjuvant immunotherapy
and surgery for cancer treatment.Clin. Cancer Res. 25 ,
5743 – 5751 (2019). doi:10.1158/1078-0432.CCR-18-2641;
pmid: 31040150 - R. Nandaet al., Pembrolizumab plus standard neoadjuvant
therapy for high-risk breast cancer (BC): Results from I-SPY 2.
J. Clin. Oncol. 35 , 506–506 (2017). doi:10.1200/
JCO.2017.35.15_suppl.506 - P. Schmidet al., KEYNOTE-522: Phase III study of
pembrolizumab (pembro) + chemotherapy (chemo) vs placebo
Topalianet al.,Science 367 , eaax0182 (2020) 31 January 2020 8of9
RESEARCH | REVIEW